December 26, 2023 11:58 AM EST

FDA declines to grant Amgen’s Lumakras full approval in lung cancer after negative advisory committee vote

The FDA rejected Amgen’s bid to convert Lumakras’ accelerated approval into a full approval in lung cancer, the biopharma company

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA de­clines to grant Am­gen’s Lumakras full ap­proval in lung can­cer af­ter neg­a­tive ad­vi­so­ry com­mit­tee vote